Rigel to cut 30 jobs, focus on three drug programs

http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/09/rigel-fostamatinib-itp-rigl-layoffs.html

Rigel Pharmaceuticals Inc. will cut 30 jobs, mostly in R&D, and dump its once-promising rheumatoid arthritis program after the failure of another drug in a recent mid-stage trial.